文献速递睡眠呼吸障碍肺栓塞与肺血管病

无创通气与CPAP对肥胖低通气综合征患者超声心动图改变的影响

Echocardiographic changes with non-invasive ventilation and CPAP in obesity hypoventilation syndrome.
PubMed 文献 · Thorax · 2017-11-16

本研究为Pickwick项目的事后分析(n=221),比较2个月无创通气(NIV,n=71)、CPAP(n=80)与生活方式干预(对照组,n=70)对肥胖低通气综合征(OHS)患者超声心动图结构功能的影响。结果显示仅NIV降低收缩期肺动脉压和左心室质量指数并改善6分钟步行距离,CPAP无此效应。

要点

  • 仅NIV降低OHS患者收缩期肺动脉压(-3.4 mm Hg,95%CI -5.3至-1.5)。
  • 仅NIV降低左心室质量指数(-5.7 g/m2,95%CI -11.0至-4.4)。
  • 仅NIV改善6分钟步行距离(32 m,95%CI 19至46)。

核心结论

  • 在中重度OHS患者中,中期NIV治疗在改善肺动脉高压、左心室肥厚和功能结局方面优于CPAP和生活方式干预。

研究设计与样本

  • 研究为Pickwick项目多中心随机对照试验的二次分析,共纳入221例OHS患者。
  • 患者随机接受2个月NIV(n=71)、CPAP(n=80)或生活方式干预(对照组,n=70)。
  • 基线和2个月时行常规经胸二维和多普勒超声心动图,判读者对治疗分组设盲。
  • 统计分析采用意向性治疗分析。

主要发现

  • 基线时55%的患者存在肺动脉高压,51%有左心室肥厚证据。
  • NIV组收缩期肺动脉压降低3.4 mm Hg(95%CI -5.3至-1.5),与对照组比较校正P=0.025,与CPAP组比较P=0.033。
  • 基线有肺动脉高压者接受NIV后收缩期肺动脉压改善更明显(-6.4 mm Hg,95%CI -9至-3.8)。
  • 仅NIV组左心室质量指数显著降低(-5.7 g/m2,95%CI -11.0至-4.4),校正分析后NIV优于对照组(P=0.015)。
  • 仅NIV组6分钟步行距离显著改善(32 m,95%CI 19至46)。

临床怎么用

  • 对OHS合并肺动脉高压或左心室肥厚患者,可优先考虑NIV治疗以改善心脏结构和功能。
  • CPAP虽可改善通气,但本研究未显示其对超声心动图指标和运动能力的益处。

局限性

  • 本研究为二次分析,结论需长期研究确认。
  • 随访时间仅2个月,为中期结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE: Despite a significant association between obesity hypoventilation syndrome (OHS) and cardiac dysfunction, no randomised trials have assessed the impact of non-invasive ventilation (NIV) or CPAP on cardiac structure and function assessed by echocardiography. OBJECTIVES: We performed a secondary analysis of the data from the largest multicentre randomised controlled trial of OHS (Pickwick project, n=221) to determine the comparative efficacy of 2 months of NIV (n=71), CPAP (n=80) and lifestyle modification (control group, n=70) on structural and functional echocardiographic changes. METHODS: Conventional transthoracic two-dimensional and Doppler echocardiograms were obtained at baseline and after 2 months. Echocardiographers at each site were blinded to the treatment arms. Statistical analysis was performed using intention-to-treat analysis. RESULTS: At baseline, 55% of patients had pulmonary hypertension and 51% had evidence of left ventricular hypertrophy. Treatment with NIV, but not CPAP, lowered systolic pulmonary artery pressure (-3.4 mm Hg, 95% CI -5.3 to -1.5; adjusted P=0.025 vs control and P=0.033 vs CPAP). The degree of improvement in systolic pulmonary artery pressure was greater in patients treated with NIV who had pulmonary hypertension at baseline (-6.4 mm Hg, 95% CI -9 to -3.8). Only NIV therapy decreased left ventricular hypertrophy with a significant reduction in left ventricular mass index (-5.7 g/m2; 95% CI -11.0 to -4.4). After adjusted analysis, NIV was superior to control group in improving left ventricular mass index (P=0.015). Only treatment with NIV led to a significant improvement in 6 min walk distance (32 m; 95% CI 19 to 46). CONCLUSION: In patients with OHS, medium-term treatment with NIV is more effective than CPAP and lifestyle modification in improving pulmonary hypertension, left ventricular hypertrophy and functional outcomes. Long-term studies are needed to confirm these results. TRIAL REGISTRATION NUMBER: Pre-results, NCT01405976 (https://clinicaltrials.gov/).

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Corral J, Mogollon MV, Sánchez-Quiroga MÁ, et al. Echocardiographic changes with non-invasive ventilation and CPAP in obesity hypoventilation syndrome. Thorax. 2017. PMID: 29146865. doi:10.1136/thoraxjnl-2017-210642

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。